AR108139A1 - B7-H3 UNION MOLECULES, DRUGS OF THE SAME ANTIBODY AND METHODS OF USE OF THE SAME - Google Patents
B7-H3 UNION MOLECULES, DRUGS OF THE SAME ANTIBODY AND METHODS OF USE OF THE SAMEInfo
- Publication number
- AR108139A1 AR108139A1 ARP170100949A ARP170100949A AR108139A1 AR 108139 A1 AR108139 A1 AR 108139A1 AR P170100949 A ARP170100949 A AR P170100949A AR P170100949 A ARP170100949 A AR P170100949A AR 108139 A1 AR108139 A1 AR 108139A1
- Authority
- AR
- Argentina
- Prior art keywords
- binding
- human
- molecules
- molecule
- methods
- Prior art date
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente se dirige a moléculas de unión a B7-H3 capaces de unirse a B7-H3 humanas y no-humanas, y en particular a tales moléculas que son un reactivo cruzado con B7-H3 De un primate no humano (por ejemplo, un mono cynomolgus). La solicitud adicionalmente divulga moléculas de unión a B7-H3 que comprenden Dominios de Cadena Ligera Variable y/o Cadena Pesada Variable (VH) que se han humanizado y/o deshumanizado de manera que presentan una inmunogenicidad reducida en la administración a los sujetos receptores. También divulga moléculas de unión a B7-H3 biespecíficas, triespecíficas o multiespecíficas, que incluyen diacuerpos biespecíficos, BiTEs, anticuerpos biespecíficos, moléculas de unión trivalentes, etc. que comprenden: (i) tales Dominios Variables de unión a B7-H3 y (ii) un dominio capaz de unirse un epítopo de una molécula presente en la superficie de una célula efectora. La solicitud también se dirige a composiciones farmacéuticas que contiene cualquiera de tales Moléculas de unión a B7-H3, y a métodos que involucran el uso de cualquiera de tales Moléculas de unión a B7-H3 en el tratamiento de cáncer y otras enfermedades y padecimientos. La solicitud también particularmente divulga una molécula que comprende los dominios de unión a B7-H3 humanos de un conjugado de anticuerpo B7-H3 anti-humano humanizado a al menos una porción de fármaco (un “B7-H3-ADC”). La solicitud también se dirige a composiciones farmacéuticas que contienen tal B7-H3-ADCs, y a métodos que involucran el uso de cualquiera de tales B7-H3-ADC en el tratamiento de cáncer y otras enfermedades y padecimientos.This is directed to B7-H3 binding molecules capable of binding to human and non-human B7-H3, and in particular to such molecules that are a cross-reactive with B7-H3 of a non-human primate (e.g., a cynomolgus monkey). The application further discloses B7-H3 binding molecules that comprise Variable Light Chain and / or Variable Heavy Chain (VH) Domains that have been humanized and / or dehumanized so that they have reduced immunogenicity in administration to recipient subjects. It also discloses bispecific, trypecific or multispecific B7-H3 binding molecules, which include bispecific diabodies, BiTEs, bispecific antibodies, trivalent binding molecules, etc. which comprise: (i) such Variable Domains binding to B7-H3 and (ii) a domain capable of binding an epitope of a molecule present on the surface of an effector cell. The application is also directed to pharmaceutical compositions containing any such B7-H3 binding molecule, and to methods that involve the use of any such B7-H3 binding molecule in the treatment of cancer and other diseases and conditions. The application also particularly discloses a molecule comprising the human B7-H3 binding domains of a humanized anti-human B7-H3 antibody conjugate to at least a portion of drug (a "B7-H3-ADC"). The request is also directed to pharmaceutical compositions containing such B7-H3-ADCs, and to methods that involve the use of any such B7-H3-ADC in the treatment of cancer and other diseases and conditions.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323228P | 2016-04-15 | 2016-04-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR108139A1 true AR108139A1 (en) | 2018-07-18 |
Family
ID=63036884
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP170100949A AR108139A1 (en) | 2016-04-15 | 2017-04-12 | B7-H3 UNION MOLECULES, DRUGS OF THE SAME ANTIBODY AND METHODS OF USE OF THE SAME |
Country Status (1)
| Country | Link |
|---|---|
| AR (1) | AR108139A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024001470A1 (en) * | 2022-06-30 | 2024-01-04 | 南京北恒生物科技有限公司 | Antibody targeting b7-h3 and use thereof |
-
2017
- 2017-04-12 AR ARP170100949A patent/AR108139A1/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024001470A1 (en) * | 2022-06-30 | 2024-01-04 | 南京北恒生物科技有限公司 | Antibody targeting b7-h3 and use thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2018010919A2 (en) | Novel b7-h3 binding molecules, antibody-drug conjugates thereof and methods of use thereof | |
| CO2018005932A2 (en) | Bispecific molecules that have immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| MX2024007358A (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof. | |
| UY37127A (en) | MOLECULES OF UNION TO ROR1, AND METHODS OF USE OF THE SAME | |
| PE20190970A1 (en) | ANTI-CD40 ANTIBODIES AND THEIR USES | |
| PE20211767A1 (en) | ANTI-HLA-G ANTIBODIES, COMPOSITIONS INCLUDING ANTI-HLA-G ANTIBODIES AND METHODS OF USE OF ANTI-HLA-G ANTIBODIES | |
| AR109715A1 (en) | ANTI-CD27 ANTIBODIES | |
| JP2019510733A5 (en) | ||
| EA202091590A1 (en) | ANTIBODIES AGAINST PD-L1 AND THEIR APPLICATION OPTIONS | |
| AR085600A1 (en) | BISPECIFIC UNION AGENTS | |
| PE20170912A1 (en) | ANTIBODY-DRUG CONJUGATES | |
| PE20141908A1 (en) | CD47 ANTIBODIES AND METHODS OF USE THEM | |
| PE20131403A1 (en) | ANTI-OX40 ANTIBODIES AND METHODS OF USING THEM | |
| PE20121552A1 (en) | MATURE AFFINITY HUMANIZED ANTI-CEA MONOCLONAL ANTIBODIES | |
| PE20120079A1 (en) | IMPROVED ANTIBODY MOLECULES | |
| PE20210517A1 (en) | ANTI-HLA-G ANTIBODIES AND THE USE OF THEM | |
| WO2019160751A3 (en) | Methods for treating cancer with anti-pd-1 antibodies | |
| WO2019204462A3 (en) | Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs | |
| WO2018119196A8 (en) | Immunoconjugates targeting adam9 and methods of use thereof | |
| EA201892367A1 (en) | INTRODUCTION OF BISPECIFIC CONSTRUCTION CONNECTED WITH CD33 AND CD3 TO APPLY IN THE METHOD OF TREATING MYELOID LEUKEMIA | |
| PE20231080A1 (en) | ANTIBODIES THAT BIND CD3 AND CD19 | |
| PE20211296A1 (en) | ANTI-PMEL17 ANTIBODIES AND CONJUGATES THEREOF | |
| MX2020013466A (en) | Immunoconjugates targeting adam9 and methods of use thereof. | |
| MX2019007404A (en) | Adam9-binding molecules, and methods of use thereof. | |
| MX2020012309A (en) | Optimized gp41-binding molecules and uses thereof. |